What's breaking now, across thousands of outlets.
RA Capital has already participated in four biotech financings in September. Meanwhile, Janus Henderson has been the year's most prolific backer of biotech reverse merger deals, according to Gilmartin Group.
We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.
A new CDC research center aims to better understand the possible health effects of those 21 years or younger at the time of their 9/11 exposure.
The Ebola outbreak in eastern Congo, the world's fastest-growing outbreak of the disease on record, has now spread to seven provinces in the African country, local authorities said.
A trade group representing generics and biosimilars is warning that the lack of product development could imperil billions of dollars in potential savings.
Thane, September 11, 2026: A 39-year-old man with Marfan syndrome underwent a complex heart surgery after doctors found that the aortic root, the part of the main blood vessel closest to the heart…
Plus news about Sino Biopharm and AtomVie. Yarrow gets more money: New Haven-based Yarrow Bioscience priced a $150 million offering at $26 per share {$YARW}, about $2.50 below its Thursday closing ...
